Shares of AtriCure Inc. (NASDAQ:ATRC) traded up 3.2% during trading on Wednesday . The stock traded as high as $15.02 and last traded at $14.95, with a volume of 121,024 shares trading hands. The stock had previously closed at $14.48.

Several analysts recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of AtriCure in a research note on Monday, March 14th. Zacks Investment Research upgraded shares of AtriCure from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Tuesday, May 3rd. JMP Securities assumed coverage on shares of AtriCure in a research note on Thursday, June 30th. They issued an “outperform” rating and a $25.00 price objective for the company. TheStreet cut shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Monday, May 2nd. Finally, Northland Securities assumed coverage on shares of AtriCure in a research note on Tuesday, March 29th. They issued an “outperform” rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. AtriCure has a consensus rating of “Buy” and an average price target of $24.67.

The company has a 50 day moving average price of $14.86 and a 200 day moving average price of $16.69. The stock’s market capitalization is $506.01 million.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, April 28th. The medical device company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.01. The firm had revenue of $35.90 million for the quarter, compared to the consensus estimate of $36.08 million. During the same quarter in the prior year, the company posted ($0.19) EPS. The firm’s revenue was up 19.7% on a year-over-year basis. Analysts predict that AtriCure Inc. will post ($1.19) EPS for the current year.

A number of large investors recently bought and sold shares of ATRC. Victory Capital Management Inc. increased its stake in AtriCure by 15.3% in the fourth quarter. Victory Capital Management Inc. now owns 51,647 shares of the medical device company’s stock valued at $1,159,000 after buying an additional 6,845 shares during the last quarter. Wells Fargo & Company MN increased its stake in AtriCure by 20.2% in the fourth quarter. Wells Fargo & Company MN now owns 659,070 shares of the medical device company’s stock valued at $14,789,000 after buying an additional 110,890 shares during the last quarter. Paradigm Capital Management Inc. NY increased its stake in AtriCure by 108.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 247,525 shares of the medical device company’s stock valued at $5,554,000 after buying an additional 128,700 shares during the last quarter. Finally, Tamarack Advisers LP bought a new stake in AtriCure during the fourth quarter valued at $15,708,000.

AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The Company’s Isolator Synergy System, which includes its Isolator Synergy clamps, generator and switchbox, is used for the treatment of persistent and long-standing persistent Afib in patients who are undergoing open concomitant coronary artery bypass grafting, and valve replacement or repair.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.